Give Biotechs Their Due [Diligence]
Learn Lessons Early to Avoid Those Nightmare Partnerships
Tekmira Pharmaceuticals Corp. filing a complaint alleging misappropriation of information and seeking potentially more than $1 billion in damages from RNAi partner Alnylam Pharmaceuticals Inc. might seem like a bad dream. After all, the horror stories of partnerships gone bad are the stuff of nightmares for biopharmaceutical companies looking for the right mate to advance a product.
To continue reading subscribe now to BioWorld Insight
Learn More about BioWorld Insight
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.